Academic Journals Database
Disseminating quality controlled scientific knowledge

Endoscopic treatment of vesicoureteral reflux with dextranomer/ hyaluronic acid-our experience

Author(s): Prasad Mylarappa | Prathvi | Puvvada Sandeep | Kailash B. Banale | D. Ramesh

Journal: Al Ameen Journal of Medical Sciences
ISSN 0974-1143

Volume: 06;
Issue: 03;
Start page: 260;
Date: 2013;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Vesicoureteral reflux | Dextranomer/ hyaluronic acid copolymer injection

Objectives: We report our experience with subureteral submucosal injection therapy for vesicoureteral reflux and determine the safety and efficacy in patients treated with dextranomer/ hyaluronic acid co-polymer. Background: Vesicoureteral reflux affects 1% of children and increases the chances of urinary tract infection, pyelonephritis, hypertension and chronic renal insufficiency. The aim of identifying and treating vesicoureteral reflux in children is to prevent occurrence of long term complications. Method: A total of sixty three patients aged between 1-21 years with grade III – V vesicoureteral reflux, who had failed on conservative treatment were considered for this study during February 2004 to May 2012.Vesicoureteral reflux was diagnosed by voiding cysto-urethrogram (VCUG). They underwent subureteral injection of dextranomer/ hyaluronic acid co-polymer. Results: Among the sixty three patients treated, 51(81%) were cured with single injection while a second injection raised the cure rate to 60(95%). Conclusion: The minimally invasive treatment of vesicoureteral reflux with deflux (dextranomer/ hyaluronic acid co-polymer) is an effective alternative procedure to open surgical technique requiring minimal operating time with low morbidity.
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Rapperswil
Tango Rapperswil